Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free SPEC Stock Alerts

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 92 -4.00 (-4.17%)
As of 07/24/2026 11:29 AM Eastern
Compare

SPEC vs. TSTL, BVC, AKR, ODX, and CNSL

Should you buy INSPECS Group stock or one of its competitors? MarketBeat compares INSPECS Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with INSPECS Group include Tristel (TSTL), BATM Advanced Communications (BVC), Akers Biosciences (AKR), Omega Diagnostics Group (ODX), and Cambridge Nutritional Sciences (CNSL). These companies are all part of the "medical instruments & supplies" industry.

How does INSPECS Group compare to Tristel?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

INSPECS Group has a consensus price target of GBX 60, indicating a potential downside of 34.78%. Given INSPECS Group's stronger consensus rating and higher possible upside, analysts plainly believe INSPECS Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Tristel has a beta of 0.339, meaning that its stock price is 66% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, meaning that its stock price is 61% more volatile than the broader market.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
INSPECS Group -2.67%-6.07%0.45%

In the previous week, Tristel had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for Tristel and 0 mentions for INSPECS Group. Tristel's average media sentiment score of 1.36 beat INSPECS Group's score of 0.00 indicating that Tristel is being referred to more favorably in the media.

Company Overall Sentiment
Tristel Positive
INSPECS Group Neutral

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M4.36£6.54M£16.2427.71
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A

21.6% of Tristel shares are held by institutional investors. Comparatively, 0.4% of INSPECS Group shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Comparatively, 19.6% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Tristel beats INSPECS Group on 11 of the 16 factors compared between the two stocks.

How does INSPECS Group compare to BATM Advanced Communications?

INSPECS Group (LON:SPEC) and BATM Advanced Communications (LON:BVC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

INSPECS Group currently has a consensus target price of GBX 60, suggesting a potential downside of 34.78%. Given INSPECS Group's stronger consensus rating and higher probable upside, research analysts plainly believe INSPECS Group is more favorable than BATM Advanced Communications.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
BATM Advanced Communications
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

INSPECS Group has a beta of 1.607, suggesting that its share price is 61% more volatile than the broader market. Comparatively, BATM Advanced Communications has a beta of 0.754, suggesting that its share price is 25% less volatile than the broader market.

INSPECS Group has a net margin of -2.67% compared to BATM Advanced Communications' net margin of -14.90%. INSPECS Group's return on equity of -6.07% beat BATM Advanced Communications' return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
BATM Advanced Communications -14.90%-22.13%0.58%

In the previous week, BATM Advanced Communications had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for BATM Advanced Communications and 0 mentions for INSPECS Group. BATM Advanced Communications' average media sentiment score of 0.66 beat INSPECS Group's score of 0.00 indicating that BATM Advanced Communications is being referred to more favorably in the news media.

Company Overall Sentiment
INSPECS Group Neutral
BATM Advanced Communications Positive

BATM Advanced Communications has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than BATM Advanced Communications, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A
BATM Advanced Communications£123.20M0.39-£278.26K-£4.20N/A

0.4% of INSPECS Group shares are held by institutional investors. Comparatively, 16.6% of BATM Advanced Communications shares are held by institutional investors. 19.6% of INSPECS Group shares are held by company insiders. Comparatively, 31.0% of BATM Advanced Communications shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

INSPECS Group and BATM Advanced Communications tied by winning 8 of the 16 factors compared between the two stocks.

How does INSPECS Group compare to Akers Biosciences?

Akers Biosciences (LON:AKR) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

0.4% of INSPECS Group shares are owned by institutional investors. 19.6% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

INSPECS Group has a consensus price target of GBX 60, indicating a potential downside of 34.78%. Given Akers Biosciences' higher probable upside, equities research analysts plainly believe Akers Biosciences is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akers Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Akers Biosciences' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Akers Biosciences Neutral
INSPECS Group Neutral

Akers Biosciences has a net margin of 0.00% compared to INSPECS Group's net margin of -2.67%. Akers Biosciences' return on equity of 0.00% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Akers BiosciencesN/A N/A N/A
INSPECS Group -2.67%-6.07%0.45%

Akers Biosciences has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Akers Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akers Biosciences£2.32M0.00N/A-£129.60N/A
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A

Summary

INSPECS Group beats Akers Biosciences on 7 of the 11 factors compared between the two stocks.

How does INSPECS Group compare to Omega Diagnostics Group?

INSPECS Group (LON:SPEC) and Omega Diagnostics Group (LON:ODX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Omega Diagnostics Group'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Omega Diagnostics Group Neutral

INSPECS Group has a net margin of -2.67% compared to Omega Diagnostics Group's net margin of -51.15%. INSPECS Group's return on equity of -6.07% beat Omega Diagnostics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Omega Diagnostics Group -51.15%-29.14%-10.53%

Omega Diagnostics Group has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Omega Diagnostics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A

0.4% of INSPECS Group shares are held by institutional investors. Comparatively, 29.8% of Omega Diagnostics Group shares are held by institutional investors. 19.6% of INSPECS Group shares are held by insiders. Comparatively, 50.6% of Omega Diagnostics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

INSPECS Group currently has a consensus target price of GBX 60, suggesting a potential downside of 34.78%. Given Omega Diagnostics Group's higher possible upside, analysts plainly believe Omega Diagnostics Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Omega Diagnostics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

INSPECS Group has a beta of 1.607, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Omega Diagnostics Group has a beta of 3.85, meaning that its stock price is 285% more volatile than the broader market.

Summary

INSPECS Group beats Omega Diagnostics Group on 7 of the 13 factors compared between the two stocks.

How does INSPECS Group compare to Cambridge Nutritional Sciences?

Cambridge Nutritional Sciences (LON:CNSL) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Cambridge Nutritional Sciences has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, suggesting that its share price is 61% more volatile than the broader market.

Cambridge Nutritional Sciences has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Nutritional Sciences£8.06M0.53-£3.03M£0.603.00
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A

In the previous week, Cambridge Nutritional Sciences' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Cambridge Nutritional Sciences Neutral
INSPECS Group Neutral

Cambridge Nutritional Sciences has a net margin of 16.94% compared to INSPECS Group's net margin of -2.67%. Cambridge Nutritional Sciences' return on equity of 12.15% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Nutritional Sciences16.94% 12.15% -2.36%
INSPECS Group -2.67%-6.07%0.45%

1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. Comparatively, 0.4% of INSPECS Group shares are owned by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are owned by insiders. Comparatively, 19.6% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 34.78%. Given INSPECS Group's stronger consensus rating and higher possible upside, analysts plainly believe INSPECS Group is more favorable than Cambridge Nutritional Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambridge Nutritional Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Cambridge Nutritional Sciences beats INSPECS Group on 8 of the 14 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

Export
MetricINSPECS GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£104.81M£3.14B£7.06B£2.58B
Dividend Yield2.00%1.93%2.67%6.17%
P/E Ratio-9.7917.0427.14368.39
Price / Sales0.52115.72582.3084,422.84
Price / Cash1.63146.5449.8127.89
Price / Book0.922.6410.287.41
Net Income-£4.11M£99.80M£3.60B£5.89B
7 Day Performance-6.12%-2.00%-1.27%0.39%
1 Month Performance-8.00%-0.78%-1.67%0.27%
1 Year Performance113.95%-4.23%18.25%68.12%

INSPECS Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
N/AGBX 92
-4.2%		GBX 60
-34.8%		+114.0%£104.81M£191.70MN/A1,673
TSTL
Tristel
N/AGBX 381.50
+0.4%		N/A+21.6%£183.11M£49.54M23.49208
BVC
BATM Advanced Communications
N/AGBX 13.60
-4.6%		N/A-12.7%£46.25M£123.20MN/A980
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32MN/A120
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55MN/A91

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SPEC) was last updated on 7/26/2026 by MarketBeat.com Staff.
From Our Partners
The comeback story of the century (ticker inside)
In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of ...
InvestorPlace | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
The 90%-off options that empty accounts
A call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...
Profits Run | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel